Track topics on Twitter Track topics that are important to you
WASHINGTON, Aug. 8, 2017 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against NxStage Medical, Inc. (NASDAQ: NXTM) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by Fresenius Medical Care for $30.00 per share in cash. The transaction is valued at approximately $2 billion and is expected to close in 2018.
If you are a NxStage Medical, Inc. shareholder and are interested in obtaining additional information regarding this investigation, please visit us at: http://www.rowleylawpllc.com/investigation/nxstage. You may also contact Danielle Rowland Lindahl, Esq. at Rowley Law PLLC, 2316 Rhode Island Ave NE, Washington, DC 20018, by email at email@example.com, or by telephone at 202-800-3501 or 844-400-4643 (toll-free).
Rowley Law PLLC represents shareholders nationwide in class actions and derivative lawsuits in complex corporate litigation. For more information about the firm and its attorneys, please visit http://www.rowleylawpllc.com.
Attorney Advertising. Prior results do not guarantee a similar outcome.
SOURCE Rowley Law PLLCNEXT ARTICLE
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...